ArticleUnited European gastroenterology journal2025
Systematic Evaluation of Helicobacter pylori Susceptibility to Antibiotics Before First-Line Treatment: A Cohort Study.
Article in United European gastroenterology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Systematic Evaluation of Helicobacter pylori Susceptibility to Antibiotics Before First-Line Treatment: A Cohort Study.United European gastroenterology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEuropean guidelines recommend that susceptibility tests be routinely performed, even before prescribing first-line treatment of Helicobacter pylori infection. However, empirical treatments are the rule in France, and susceptibility-guided treatments are the exception.
objectiveWe aimed to report our experience of systematic antibiotic susceptibility testing before first-line treatment.
methodsProspective registration of all esofagogastroduodenoscopies performed in a community hospital from December 2023 to December 2024. Antral and fundic biopsies were performed, at the discretion of the endoscopist, for histological examination, polymerase chain reaction (PCR) and culture without any freezing.
resultsOverall, 3566 adults underwent esofagogastroduodenoscopy, 1785 (50.1%) were tested and H. pylori infection was diagnosed in 308 (17.3%) [95% confidence interval (CI): 15.5%-19.0%] individuals. The sensitivity of PCR for the diagnosis of H. pylori infection was 99.7%, significantly higher than those of histology (94.1%) and culture (95.2%) (p < 0.01). Clarithromycin resistance was observed in 22.6% [95% CI: 17.9%-27.3%] and levofloxacin resistance in 18.6% [95% CI: 14.1%-23.2%] of cases. Among 285 patients treated, susceptibility-guided triple therapy was prescribed in 84.9% of cases (73.3% amoxicillin-clarithromycin, 11.6% amoxicillin-levofloxacin) and quadruple bismuth therapy in 14.4% of cases. The eradication rates were 98.1% [95% CI: 96.0%-100%] for triple therapy amoxicillin-clarithromycin and 100% [95% CI: 100%-100%] for amoxicillin-levofloxacin, significantly higher than 81.3% [95% CI: 67.7%-94.8%] for quadruple bismuth therapy (p < 0.01 and p = 0.03, respectively). Overall, of 218 (70.8%) patients evaluated by the C13 urea breath test, H. pylori was eradicated in 209 (95.9%) [95% CI: 93.2%-98.5%] patients. The PCR-based diagnostic and therapeutic strategy was more cost-effective than the immunohistochemistry-based strategy.
conclusionA PCR-based susceptibility-guided strategy is easy to implement in routine clinical practice. In more than 7 in 10 patients, PCR enabled the offer of a susceptibility-guided triple therapy that was more effective and less costly than empirical quadruple bismuth therapy. Culture enabled one additional patient in 10 to be offered a susceptibility-guided triple therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.